Organ Transplant Immunosuppressant Drugs Market: Dynamics and Opportunities Report by Transparency Market Research

The global organ transplant immunosuppressant drugs market is fairly consolidated, with the top 5 vendors contributing over 90% of the market in 2014. Transparency Market Research (TMR) notes that these leading companies–Novartis AG, Astellas Pharma, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Sanofi–are offering a robust and diverse product portfolio, including blockbuster drugs, to consolidate their market shares. They are updating their pipelines after the impending patient expiry of blockbuster drugs.

The increasing incidence rate of various life-threatening ailments has stimulated the demand for organ replacement therapies and transplants as the last line of treatment to treat organ failures or disabilities. This is a key driver fuelling the growth of the market. According to the TMR’s estimation, the global organ transplant immunosuppressant market was valued at US$5.1 bn in 2014. The market is anticipated to register a CAGR of -5.0% between 2015 and 2023 with the market’s valuation estimated to reach US$3.2 bn by 2023.

This 102 page report gives readers a comprehensive overview of the organ transplant immunosuppressant drugs market. Browse to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

Immunosuppressant Drugs for Successful Kidney Transplantation Propel Market Growth

Over the last couple of years, kidney transplantation has emerged as the preferred treatment method for end-stage kidney disorder, as the replacement proves to be more cost-effective than dialysis. The use of immunosuppressant drugs has been considered as a vital element for the long-term success of kidney transplants. According to findings by TMR, the segment occupied over 53.4% of the market in 2014 and is expected to lead the market through 2023. Rising incidence rate of kidney disorders is expected to fuel the growth of this segment. Furthermore, the rising incidence other of chronic ailments, which may need liver, heart, and lung transplants, mainly among geriatric population, is expected to spur the demand for organ transplant immunosuppressant drugs.

In addition, the emerging demand for bone marrow transplant has expedited the discovery of novel immunosuppressant drugs and therapies. Recent developments suggest that immunosuppression is found to offer promising line of treatment for the management of graft-versus-host diseases.

High Cost of Organ Replacement Surgeries may Act as Restraint

The high cost of organ transplant procedures, significant shortage of donors, and the considerable expenditure required for the care of patients post-transplantation are likely to restrain the growth of the market in some regions. Combined with them, the non-adherence of the immunosuppression therapies after transplantation owing to the lack of awareness among patients is another key restraining factor. Additionally, uncertainty of benefits of the use of immunosuppression for complex transplantation procedures, especially evident in case of liver transplantation, has impeded the market growth. In addition, the advent of stem cell therapies as a potential substitute for organ transplantation may restrict the growth of the global organ transplant immunosuppressant drugs market.

However, extensive clinical studies and R&D activities undertaken to develop and test novel immunosuppressant therapeutics is a key trend that will help minimize the cases of organ rejection for a number of transplantations, unlocking promising growth opportunities for the market players.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving organ transplant immunosuppressant drugs market during 2015 - 2023: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967

Robust Healthcare Infrastructure to Spur Demand for Organ Transplant Immunosuppressant Drugs in North America

Regionally, North America is a prominent market for organ transplant immunosuppressant drugs. The growth is driven by the increasing rate of successful organ replacement surgeries and substantial investments from the government and private players to develop a robust healthcare infrastructure.

Europe is another region exhibiting tremendous potential for growth in the organ transplant immunosuppressant drugs market. Continuous advancements in surgical procedures for organ transplantation and innovations in immunosuppressant drug discovery are the crucial factors propelling the market growth in the region.

The study presented here is based on a report by Transparency Market Research (TMR) titled “Organ Transplant Immunosuppressant Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.”

Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.